Dyskinetic activity

Dyskinetic activity. A 4-week dose escalation study was performed to assess the safety and tolerability of cannabis in six patients with Parkinson s disease (PD) with levodopa (L-DOPA)-induced dyskinesia. 

With increasing dose, the incidence of dyskinetic activity increases. In addition, with time, the effects may manifest at a constant, previously well-tolerated dose, indicating possible development of receptor suspersensitivity. 

Dose-related shifts in predominant EEG frequency for PCP and several phencyclinoids are shown in figure 3. For all 10 compounds tested, there was a shift in predominant EEG frequency into the theta range across the lower doses, associated primarily with increased locomotor activity and stereotyped behaviors. With further increases in dose, PCP and all of its analogues produced shifts to lower predominant frequencies, which typically fell between 2 and 4 Hz. As the dose was incremented geometrically, the lower frequency EEG waves were associated first with ataxia, then with dyskinetic movements, catalepsy, and possibly seizure activity. SKF-10,047 also produced ataxia, but was unique in that it did not cause a shift to a lower predominant frequency and produced only EEG theta activity at all subconvulsant doses. 

Tardive dyskinesia Tardive dyskinesia, a syndrome consisting of potentially irreversible, involuntary, dyskinetic movements may develop in patients treated with neuroleptics (eg, antipsychotics). Amoxapine is not an antipsychotic, but it has substantive neuroleptic activity. 

Two phencyclidine-intoxicated patients had bizarre combinations of disorientation, hallucination, agitation, and dyskinetic motor activity (27). 

---